Trial reportAntimicrobial agents and chemotherapy2010
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
Trial report in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Population Pharmacokinetics of Tigecycline and Implications for Individualized Therapy Optimization: A Systematic Review.Drug design, development and therapy · 2025Pooled it
- Population Pharmacokinetics of Tigecycline: A Systematic Review.Drug design, development and therapy · 2022Pooled it
- Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.Antimicrobial agents and chemotherapy · 2013Trial
- Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.Antimicrobial agents and chemotherapy · 2012Trial
- Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.Antimicrobial agents and chemotherapy · 2012Trial
- Application of Machine Learning Models to Predict Tigecycline Exposure in Critically Ill Patients Using Different Limited Sampling Strategies.Drug design, development and therapy · 2026Article
- Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling.Frontiers in pharmacology · 2024Article
- Physicochemical Characteristics of Antimicrobials and Practical Recommendations for Intravenous Administration: A Systematic Review.Antibiotics (Basel, Switzerland) · 2023Review
- The Monte Carlo Simulation of Three Antimicrobials for Empiric Treatment of Adult Bloodstream Infections With Carbapenem-Resistant Enterobacterales in China.Frontiers in microbiology · 2021Article
- Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study.BMC microbiology · 2020Article
- Establishment and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Tigecycline in Critically Ill Patients.International journal of analytical chemistry · 2020Article
- Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007).Infectious diseases and therapy · 2019Article
- Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.Antimicrobial agents and chemotherapy · 2019Article
- Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock.Antimicrobial agents and chemotherapy · 2018Article
- Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.Antimicrobial agents and chemotherapy · 2017Article
- Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.Antimicrobial agents and chemotherapy · 2017Article
- Diet-Induced Obesity Does Not Alter Tigecycline Treatment Efficacy in Murine Lyme Disease.Frontiers in microbiology · 2017Article
- Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease.Antimicrobial agents and chemotherapy · 2016Article
- In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.Antimicrobial agents and chemotherapy · 2014Article
- Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.Infection and drug resistance · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline is a new-generation of tetracycline (glycylcyclines) and is active in vitro against bacteria that possess any of the classical genes that confer tetracycline resistance through ribosomal protection or efflux pumps. Herein, tigecycline disposition in patients with community- or hospital-acquired pneumonia was described using a population pharmacokinetic model. Additionally, the influence of covariates, such as body surface area, severity of illness, and clinical laboratory measures, on tigecycline disposition was evaluated. An intravenous loading dose of 100 mg was followed by 50 mg of tigecycline every 12 h. The final population pharmacokinetic model was a two-compartment model with linear elimination and with a relationship between tigecycline clearance and body surface area and creatinine clearance. The model was parameterized using total clearance (CL), the volume of the central compartment, distributional clearance from the central to the peripheral compartment, and volumes of distribution at steady state. Relationships between body surface area and creatinine clearance were identified as significant predictors of interindividual variability on CL. This model will serve as the basis for estimating tigecycline exposure for pharmacokinetic-pharmacodynamic analyses for efficacy and safety among patients with community- or hospital-acquired pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.